Previous 10 | Next 10 |
A pilot study by researchers from the Medical University of South Carolina has revealed that an FDA-approved drug could help reduce the need for opioid administration after surgery. Scientists from the university’s Department of Anesthesia and Perioperative Medicine (MUSC) found that an ...
A newly found compound, CBD3063, has shown that it can be significantly effective at treating chronic pain in animal studies with barely any side effects. Scientists discovered the compound after screening a whopping 27 million potential drugs extensively. CBD3063 works by targeting the Cav2....
SOHM (OTC: SHMN) , a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, has filed a provisional patent application on its ABBIE Smart Gene-Editing platform. According to the announcement, the platform uses th...
2024-01-09 09:56:26 ET More on SOHM, Inc. Financial information for SOHM, Inc. For further details see: SOHM files provisional patent on its ABBIE ‘smart gene-editing’ platform
CHINO HILLS, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN) (the “Company”), a pharmaceutical, nutraceutical, cosmeceutical and biotech Company that manufactures and markets generic drugs covering numerous treatment categories, announces today t...
The U.S. Food and Drug Administration has announced that changes to safety labeling requirements for opioid medications are receiving final approval and implementation. These changes are part of the agency’s ongoing efforts to address the country’s opioid overdose epidemic , a cr...
SOHM is launching a line of 13 new chewables that offer a range of health benefits and expand the company’s preventative care product portfolio The new line will be available online through Amazon.com and the company’s direct-to-consumer website and will be showcased at industry c...
SOHM (OTC: SHMN) is a recognized generic pharmaceutical manufacturer with operations spanning India, the Philippines, Uganda, the U.S., U.K. and EU. The company aims to create and produce cutting-edge generic medications that span a wide range of treatment areas, all while ensuring top-tier qual...
A Senate Committee meeting has revealed that experts are worried about the impact of critical drug shortages on the American public. Anderson Cancer Center’s Lymphoma Clinical Research program director Dr. Jason Westin recently testified before the U.S. Senate Committee on Finance and to...
SOHM recently acquired ABBIE, a world-class gene-editing platform capable of inserting larger DNA sequences, including full genes, into a desired location of the target cell’s genome ABBIE is poised to facilitate drug development, with SOHM confident that its new gene-editing technology ...
News, Short Squeeze, Breakout and More Instantly...
Sohm Inc Company Name:
SHMN Stock Symbol:
OTCMKTS Market:
2024-06-10 13:45:34 ET CAR T-cell therapy has seen significant growth and much promise, as it provides targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiatio...
CHINO HILLS, CA / ACCESSWIRE / June 10, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnology company that manufactures and markets generic drugs covering numerous treatment categories, announced that preliminary data from a 3 rd party user resulted in AB...
SOHM (OTC: SHMN) , a leading generic pharmaceutical and upstart biotechnology company, today announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. The technology holds the potential to revolutionize gen...